A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study

Diabetes Res Clin Pract. 2021 Sep:179:108998. doi: 10.1016/j.diabres.2021.108998. Epub 2021 Aug 11.

Abstract

Aim: Our previous study revealed that sarcopenia was frequently observed in subjects with type 1 diabetes mellitus (T1DM). However, the factors associated with sarcopenia that are related to T1DM have not yet been clarified. Insulin-like growth factor-1 (IGF-1) has been shown to play a role in skeletal muscle growth, differentiation, and regeneration. The present study, therefore, investigated the association between the serum IGF-1 level and sarcopenia and low skeletal muscle mass in subjects with T1DM.

Methods: This cross-sectional study enrolled subjects with T1DM (n = 168) and without diabetes (n = 59) who had had their clinical data on serum IGF-1 collected in the iDIAMOND study.

Results: The z-score of serum IGF-1 was significantly lower in the subjects with T1DM than that in those without diabetes (p < 0.001). Among subjects with T1DM, the z-score of serum IGF-1 was significantly lower in sarcopenic subjects than in non-sarcopenic subjects. The multivariable logistic regression analysis showed that the serum IGF-1 z-score was an independent determinant of sarcopenia and a low skeletal muscle mass index, but not low grip strength nor slow gait speed in subjects with T1DM.

Conclusions: A low serum IGF-1 level is correlated with sarcopenia and low skeletal muscle mass in subjects with T1DM.

Keywords: Sarcopenia; Serum IGF-1; Skeletal muscle mass; Type 1 diabetes.

MeSH terms

  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 1* / pathology
  • Hand Strength
  • Humans
  • Insulin-Like Growth Factor I / metabolism*
  • Muscle, Skeletal / pathology
  • Sarcopenia* / epidemiology
  • Sarcopenia* / etiology
  • Sarcopenia* / pathology

Substances

  • Insulin-Like Growth Factor I